The financing will in part support development of the firm's PI3K inhibitor paxalisib in PIK3CA-mutated brain cancer and HER2-positive breast cancer.

This month, the firm also performed a 1-for-15 reverse share split to maintain compliance with Nasdaq listing requirements.

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

Despite regulatory setbacks, the petitioners believe that survival and other data they've collected themselves are worth ...

The platform will support Anocca's Phase I/II trial of its therapies under development for treating KRAS-mutated pancreatic cancer.

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.

BE-101 is an engineered B-cell therapy, in which a functional copy of the FIX gene is inserted into patients' own B cells in vivo.

Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...